THE APEX TIMES
mRNA Therapeutics Market Outlook report points to expanding oncology and rare-disease pipelines through 2035, with Moderna among profiled companies
A new market outlook study published via Globe Newswire projects growth in mRNA therapeutics driven by oncology and rare-disease development efforts, delivery-technology advances, and partnerships, profiling Moderna alongside peers including BioNTech and CureVac.
A third-party mRNA therapeutics market outlook study released on August 26, 2026, projects continued industry expansion through 2035 and highlights a set of themes the report says are shaping the sector. The study, distributed through Globe Newswire and syndicated by Yahoo Finance, frames growth around expanding oncology and rare-disease pipelines, strategic partnerships, and advances in delivery technologies, which it says are helping broaden the clinical and commercial footprint of mRNA-based medicines.
The report, titled “mRNA Therapeutics Market Outlook Report 2026-2035,” includes company profiles spanning established players and emerging developers. In addition to Moderna, the profile list named Arcturus Therapeutics, BioNTech, CureVac, Providence Therapeutics, RNAimmune, and Recode Therapeutics, among others.
Moderna is specifically included in the study’s company-by-company outlook, reflecting investor and industry attention on how large mRNA platforms are competing not only in vaccine-adjacent areas, but increasingly across oncology and rare disease indications. While the announcement does not provide Moderna-specific pipeline milestones in the material available for this review, it places the company within a broader market narrative centered on modality scaling and platform maturation.
One of the key messages attributed to the report is that the mRNA therapeutics market is being driven by both product development and the supporting “how you deliver it” infrastructure. Delivery technology, in this context, refers to the systems and formulations used to get mRNA into target cells effectively and safely, a factor that can influence efficacy, tolerability, and the practicality of expanding indications. The release ties delivery advances to the expected market growth through 2035.
Strategic partnerships are also listed as a contributor to growth. In mRNA therapeutics, partnerships can cover a range of collaborations, including co-development, technology sharing, and regional commercialization arrangements. The published excerpt does not name specific deals involving Moderna, but it positions partnerships as part of the sector’s go-to-market and development strategy.
The study’s framing suggests that oncology and rare diseases are expected to remain central to how companies differentiate. Oncology often requires multi-factor decision-making around dosing schedules, combination regimens, and patient selection, while rare disease programs can depend on smaller trial populations and more targeted endpoints. The release does not provide trial results or regulatory timelines in the text available here, but it explicitly connects pipeline expansion in these areas to the report’s projected growth.
For Moderna, the practical takeaway from the announcement is not a set of quantified forecasts for the company, but rather its inclusion in a sector-wide outlook that emphasizes platform expansion, delivery progress, and partnering. Readers should treat the report as an external market assessment rather than a corporate update, since the material available for review does not include Moderna guidance, earnings metrics, or new company disclosures tied to specific programs.
What remains unclear from the available material is how the report breaks down expected market share by company, what assumptions it uses for adoption rates, pricing, and regulatory timelines, and whether it cites specific Moderna product milestones during 2026 to 2035. The August 26 release excerpt also does not provide detailed numbers, so the direction and themes are clearer than the underlying magnitude of the forecast.
Why It Matters
- The themes highlighted in the report help explain how investors and industry participants may be evaluating competitiveness in mRNA beyond early-stage platforms, focusing on delivery capability and indication expansion.
- Inclusion of Moderna among profiled companies indicates the study’s expectation that established mRNA platforms will remain central to market development through 2035.
- For the sector, delivery technologies and partnerships are positioned as non-product drivers that can affect how quickly and widely mRNA therapeutics reach new patient populations.
- Because the excerpt does not include detailed numbers or company-specific forecasts, investors and stakeholders may need to wait for the full report or additional disclosures to interpret the magnitude for each company.
Sources
Key Facts
- A market outlook study titled “mRNA Therapeutics Market Outlook Report 2026-2035” was published on August 26, 2026 via Globe Newswire and syndicated by Yahoo Finance.
- The study projects significant growth in the mRNA therapeutics market through 2035, attributing expansion to oncology and rare-disease pipeline growth, strategic partnerships, and delivery-technology advances.
- The report includes company profiles that name Moderna and multiple peers, including Arcturus Therapeutics, BioNTech, CureVac, Providence Therapeutics, RNAimmune, and Recode Therapeutics.
- The material available for review does not provide Moderna-specific pipeline updates, figures, or timelines tied to the study within the disclosed excerpt.
Healthcare Related
Ken Griffin’s bet on Eli Lilly underscores investors’ focus on obesity and Alzheimer’s drugs
A market piece pointed to billionaire Ken Griffin increasing his exposure to Eli Lilly in the second quarter, as the company’s obesity franchise and its Alzheimer’s program remain central to investor attention.
Real-world evidence points to lower healthcare use from Zepbound, while China trial and other big health-care deals draw attention
A real-world study discussed in biotech-industry coverage suggests Eli Lilly’s Zepbound could be associated with fewer hospital stays and emergency-room visits. Elsewhere in the sector, Summit and Akeso reported another China trial development, and other health-care headlines highlighted corporate dealmaking and a Johnson & Johnson approval.
Eli Lilly shares keep rising even as drug prices trend lower, according to market commentary
A market-focused post points to optimism around Eli Lilly’s demand and distribution momentum as pricing pressure continues, but notes management has already indicated net prices will go lower from here.
Atrial fibrillation market forecast through 2035 highlights widening therapy mix, including investigational monoclonal antibody approach
A market outlook published by Yahoo Finance on Aug. 26, 2026 places antiarrhythmic agents at the center of current atrial fibrillation treatment while pointing to monoclonal antibodies as an emerging, still-investigational direction. The article’s company round-up includes Johnson & Johnson alongside Abbott, Boston Scientific, Medtronic, Novartis and Sanofi.
Eli Lilly expands Alzheimer’s research collaboration with BioArctic as it builds obesity-related cost data
The company agreed a new research and collaboration deal with BioArctic, aiming to use the Swedish biotech’s BrainTransporter technology in a potential Alzheimer’s treatment, according to a report on Yahoo Finance.
David Tepper fully exited UnitedHealth in Q2, but investors are left to read the tea leaves
A report says hedge fund billionaire David Tepper sold all of his UnitedHealth position during the second quarter. The move could be a routine portfolio adjustment, a valuation call, or a risk-management step, but the public record described in the article does not offer clear guidance on motive.
Real-world analysis links Zepbound to lower healthcare costs in adults over 55 with obesity, Eli Lilly says
Eli Lilly reported results from a real-world study suggesting that people who remained on Zepbound (tirzepatide) for weight management saw lower healthcare costs than those who discontinued, in a population of adults over 55 with overweight or obesity.